| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| W D Heiss, K Herholz, G Pawlik, I Hebold, P Klinkhammer, B Szelie. Positron emission tomography findings in dementia disorders: contributions to differential diagnosis and objectivizing of therapeutic effects. The Keio journal of medicine. vol 38. issue 2. 1989-10-20. PMID:2674513. |
degenerative dementia of the alzheimer type is characterized by a metabolic disturbance most prominent in the parietooccipito-temporal association cortex and later in the frontal lobe, while primary cortical areas, basal ganglia, thalamus, and cerebellum are not affected. |
1989-10-20 |
2023-08-11 |
Not clear |
| A Sattin, B B Muhoberac, M H Aprison, C L Schau. Tetrahydroaminoacridine (THA) as a pharmacological probe in Alzheimer's disease (AD) and other neurodegenerative disorders. Medical hypotheses. vol 29. issue 3. 1989-10-13. PMID:2779475. |
tetrahydroaminoacridine (tha) as a pharmacological probe in alzheimer's disease (ad) and other neurodegenerative disorders. |
1989-10-13 |
2023-08-11 |
Not clear |
| E Masliah, R Terry, G Buzsák. Thalamic nuclei in Alzheimer disease: evidence against the cholinergic hypothesis of plaque formation. Brain research. vol 493. issue 2. 1989-10-06. PMID:2765898. |
we examined the incidence and distribution of plaques in the thalamus in order to determine whether in alzheimer's disease degenerating cholinergic processes from the nbm induce the emergence of plaques according to the cholinergic hypothesis. |
1989-10-06 |
2023-08-11 |
Not clear |
| G M Shutske, F A Pierrat, K J Kapples, M L Cornfeldt, M R Szewczak, F P Huger, G M Bores, V Haroutunian, K L Davi. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics. Journal of medicinal chemistry. vol 32. issue 8. 1989-09-07. PMID:2754707. |
compounds 1a and 1p, which showed less acute toxicity in both rats and mice than tha, are in phase ii and phase i clinical trials, respectively, for alzheimer's disease. |
1989-09-07 |
2023-08-11 |
mouse |
| J V Halliwell, E A Grov. 9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurones. European journal of pharmacology. vol 163. issue 2-3. 1989-07-12. PMID:2721578. |
the cooperativity of this latter action of tha with its well-known anticholinesterase activity is discussed in relation to the therapeutic effects of tha in treating alzheimer's disease. |
1989-07-12 |
2023-08-11 |
rat |
| D A Palmieri, D A Butterfiel. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes. Progress in clinical and biological research. vol 292. 1989-07-10. PMID:2726917. |
effects of 9-amino-1,2,3,4-tetrahydroacridine (tha), a potential drug for treatment of alzheimer's disease, on the physical state of human erythrocyte membranes. |
1989-07-10 |
2023-08-11 |
human |
| J Byrne, T Ari. Tetrahydroaminoacridine (THA) in Alzheimer's disease. BMJ (Clinical research ed.). vol 298. issue 6677. 1989-06-29. PMID:2497817. |
tetrahydroaminoacridine (tha) in alzheimer's disease. |
1989-06-29 |
2023-08-11 |
Not clear |
| S Vida, L Gauthier, S Gauthie. Canadian collaborative study of tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer's disease: effect on mood. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 34. issue 3. 1989-06-23. PMID:2655861. |
canadian collaborative study of tetrahydroaminoacridine (tha) and lecithin treatment of alzheimer's disease: effect on mood. |
1989-06-23 |
2023-08-11 |
Not clear |
| T Yamamoto, Y Iwasaki, Y Sato, H Yamamoto, H Konn. Astrocytic pathology of methionine sulfoximine-induced encephalopathy. Acta neuropathologica. vol 77. issue 4. 1989-05-26. PMID:2565645. |
prolonged mso-loading (every 12 h up to three times, 100-150 mg/kg body weight) brought about the appearance of astrocytes with swollen, watery nuclei reminiscent of alzheimer ii glia chiefly in the neocortex, hippocampus and lateral thalamus after 24 h. concomitantly, profound accumulation of glycogen ensued in the superficial three layers of the neocortex, hippocampus and pyriform cortex. |
1989-05-26 |
2023-08-11 |
rat |
| P B Reiner, E G McGee. THA increases action potential duration of central histamine neurons in vitro. European journal of pharmacology. vol 155. issue 3. 1989-04-27. PMID:3148476. |
long-term administration of 9-amino-1,2,3,4-tetrahydroacridine (tha) has been reported to produce marked clinical improvement in patients suffering from alzheimer's disease. |
1989-04-27 |
2023-08-11 |
Not clear |
| P B Reiner, E G McGee. THA increases action potential duration of central histamine neurons in vitro. European journal of pharmacology. vol 155. issue 3. 1989-04-27. PMID:3148476. |
by its effect upon action potential duration, tha may increase release of transmitter from the axon terminals of cortically projecting aminergic neurons which have been shown to degenerate in alzheimer's disease. |
1989-04-27 |
2023-08-11 |
Not clear |
| J de Belleroche, I M Gardine. Inhibitory effect of 1,2,3,4-tetrahydro-9-aminoacridine on the depolarization-induced release of GABA from cerebral cortex. British journal of pharmacology. vol 94. issue 4. 1989-02-21. PMID:3207970. |
1,2,3,4-tetrahydro-9-aminoacridine (tha) has an inhibitory effect on the activity of acetylcholinesterase which has led to its use in the treatment of alzheimer's disease. |
1989-02-21 |
2023-08-11 |
rat |
| E K Perry, C J Smith, J A Court, J R Bonham, M Rodway, J R Atac. Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neuroscience letters. vol 91. issue 2. 1988-12-22. PMID:3185960. |
tetrahydroaminoacridine (tha) has recently been reported to be more useful in the treatment of alzheimer's disease than physostigmine. |
1988-12-22 |
2023-08-11 |
human |
| G E Gibson, T Mange. Changes in cytosolic free calcium with 1,2,3,4-tetrahydro-5-aminoacridine, 4-aminopyridine and 3,4-diaminopyridine. Biochemical pharmacology. vol 37. issue 21. 1988-12-15. PMID:2847755. |
both 4-ap and tha have been used to treat alzheimer's disease. |
1988-12-15 |
2023-08-11 |
Not clear |
| B D Pearce, L T Potte. Effects of tetrahydroaminoacridine on M1 and M2 muscarine receptors. Neuroscience letters. vol 88. issue 3. 1988-07-29. PMID:3386874. |
tetrahydroaminoacridine (tha) has been reported to improve the memory of persons with alzheimer's disease, but its mechanism of action is uncertain. |
1988-07-29 |
2023-08-11 |
rabbit |
| L Hayward, H Brodat. THA and Alzheimer's disease. The Australian and New Zealand journal of psychiatry. vol 21. issue 4. 1988-06-03. PMID:3449055. |
tha and alzheimer's disease. |
1988-06-03 |
2023-08-11 |
Not clear |
| B Drukarch, J E Leysen, J C Stoo. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life sciences. vol 42. issue 9. 1988-03-29. PMID:2893967. |
further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (tha), an alleged drug for the treatment of alzheimer's disease. |
1988-03-29 |
2023-08-11 |
Not clear |
| B Drukarch, J E Leysen, J C Stoo. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life sciences. vol 42. issue 9. 1988-03-29. PMID:2893967. |
in a recent study we have documented the acetylcholinesterase and outward k+-current inhibiting activity of 9-amino-1,2,3,4-tetrahydroacridine (tha), a drug reportedly active in the treatment of alzheimer patients. |
1988-03-29 |
2023-08-11 |
Not clear |
| B Drukarch, J E Leysen, J C Stoo. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life sciences. vol 42. issue 9. 1988-03-29. PMID:2893967. |
it is concluded from these experiments that the effects of tha on monoaminergic neurotransmission might contribute to the alleged therapeutic action of tha in alzheimer's disease. |
1988-03-29 |
2023-08-11 |
Not clear |
| M M Mesulam, C Geula, M A Morá. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Annals of neurology. vol 22. issue 6. 1988-02-26. PMID:3435078. |
the histochemical distribution of cholinesterases in the cerebral cortex and their response to cholinesterase inhibitors such as physostigmine and tetrahydroaminoacridine (tha) were investigated in brains from patients with alzheimer's disease and control subjects. |
1988-02-26 |
2023-08-11 |
human |